Comprehensive bio-guided contract development and manufacturing solutions targeting viral entry blockade, enzymatic replication shutdown, and host immune homeostasis.
The global market for antiviral therapeutics, immune-supporting dietary formulations, and phytomedicines has experienced an irreversible structural transformation following recurring global respiratory crises and escalating synthetic drug resistance.
Single-target synthetic small-molecule antiviral agents (such as standard neuraminidase or protease inhibitors) frequently face rapid drug resistance due to high mutation rates in RNA viruses (Influenza A/B, Coronaviridae, Enteroviruses). The global healthcare paradigm is vigorously migrating toward standardized natural plant medicines whose multi-target poly-pharmacology blocks viral entry, stops polymerase replication, and attenuates hyper-inflammatory cytokine storms simultaneously.
Commercial consumer behavior has moved permanently from episodic post-infection intervention to persistent immunological prophylaxis. Institutional health brands, pharmacy chains, and functional food innovators across North America, Europe, and Asia are urgently looking for verified OEM manufacturers who can provide certified botanical drug substances with standardized phytochemical markers (e.g., Baicalin, Forsythoside A, Chlorogenic acid, Polysaccharides) rather than crude herbal blends.
Regulatory gatekeepers—including the US FDA under the Botanical Drug Development Guidance, the European Medicines Agency (EMA) under the HMPC framework, and China's NMPA—demand rigorous batch-to-batch chromatographic reproducibility. Generic OEM suppliers unable to provide multi-component chromatographic fingerprints, genotoxicity safety profiles, and validated bioassays are being systematically displaced from regulated supply chains.
MedGence (Yineng Pharma) provides fully integrated contract research and manufacturing services, translating raw ethnobotanical intelligence into quantifiable, defensible, and scale-manufactured antiviral therapies.
High-throughput isolation and bio-guided fraction screening of plant secondary metabolites (alkaloids, flavonoids, iridoids, polysaccharides) targeting critical viral pathways (3CLpro, RdRp, hemagglutinin).
Systematic quantification of active ingredient fluctuations across geographic origins (terroir), climate variations, harvesting windows, and anatomical plant parts to guarantee highest industrial potency.
Development and ICH-compliant validation of identity, assay, and purity protocols utilizing HPTLC, HPLC-PDA, GC-MS/MS, and multi-wavelength chromatographic fingerprint profiles.
Precision optimization of solid-liquid extraction, macroporous resin adsorption, ultrafiltration membranes, and vacuum countercurrent concentration to maximize active recovery while removing ballast.
Overcoming botanical formulation bottlenecks: thermal degradation, hygroscopicity, poor oral bioavailability, and astringent organoleptic profiles to create robust, shelf-stable dosage forms.
Rigorous safety substantiation: Median lethal dose (LD50), acute toxicity, 90-day sub-chronic repeated oral dosing, Ames reverse mutation test, and in vitro chromosomal aberration assays.
Direct measurement of virucidal efficacy: Plaque Reduction Neutralization Tests (PRNT), cytopathic effect (CPE) inhibition assays, and IC50/CC50 selectivity index determination on host cell cultures.
Viral challenge protocols utilizing validated murine and ferret models: Evaluating viral lung titers, inflammatory histopathology, lung index reduction, and survival rate prolongation.
Full GCP clinical trial design, IRB submission, participant recruitment, and pharmacokinetic/pharmacodynamic (PK/PD) clinical profiling for dietary supplements and botanical new drug candidates (NDAs).
Reverse-engineering classic multi-herb formulas (e.g., Yin Qiao San, Ma Xing Shi Gan) using network pharmacology to decode synergistic interactions, active bio-markers, and eliminate unwanted toxicity.
Scalable industrial manufacturing of standardized antiviral botanical extracts: Highly concentrated clear liquids, high-potency dry extracts, purified fractions, and vacuum-distilled volatile essential oils.
Commercial manufacturing of finished dosage forms: Automated sterile oral liquid lines, two-piece hard gelatin capsules, liquid softgels, film-coated tablets, and moisture-proof effervescent powders.
Unlike conventional synthetic monotherapies, botanical antiviral entities developed at MedGence utilize a multi-target network approach, dismantling viral pathology at every phase of the infection cycle.
| Infection Phase | Primary Biological Target | Botanical Active Classes | Molecular Action Mechanism | Analytical Standard |
|---|---|---|---|---|
| 1. Viral Attachment & Entry | Spike Glycoprotein, Hemagglutinin, ACE2 / Sialic Acid receptors | Flavonoid glycosides, Hydrolyzable tannins, Polyphenols | Stereospecific steric hindrance preventing viral envelope adhesion to human host receptors; halts membrane fusion. | HPLC-UV Assay > 90% purity; molecular binding kinetics (SPR). |
| 2. Genome Replication | RNA-dependent RNA Polymerase (RdRp), Viral 3CLpro / Mpro | Anthraquinones, Dimeric chalcones, Lignans | Competitive and allosteric active-site pocket binding; enzymatic cleavage termination of viral polyprotein precursors. | IC50 cell-free enzymatic fluorometric assay < 5.0 µg/mL. |
| 3. Viral Release & Budding | Neuraminidase (NA), Envelope protein channels | Terpenoids, Essential oil phenolics (Thymol, Cineole) | Enzymatic suppression of sialic acid cleavage; prevents newly assembled virions from budding out to infect neighboring cells. | GC-FID Fingerprint, relative retention index vs. analytical standards. |
| 4. Immunopathology Regulation | NF-κB pathway, NLRP3 inflammasome, IL-6, TNF-α | Botanical Polysaccharides, Saponins, Baicalin fractions | Suppression of excessive pro-inflammatory cascades (Cytokine Storm) while stimulating CD4+/CD8+ lymphocyte and interferon-γ release. | Immuno-turbidimetric assay, molecular weight distribution (GPC). |
Virtual screening of thousands of natural compounds in MedGence's proprietary structural database against crystallographic viral protease and polymerase structures.
Deliverable: Binding Affinity HitsDirect validation on live non-pathogenic surrogate models and target viral strains: determining Selectivity Index (SI = CC50 / IC50) to ensure high safety margins.
Deliverable: Verified Hit-to-Lead ReportTranslating lab bench extraction into 500L–3000L pilot tanks, locking critical process parameters (CPP) and critical quality attributes (CQA) under QbD principles.
Deliverable: Pilot Batch CMC DossierBringing a natural antiviral product to market requires tailored positioning that matches regional regulatory jurisdictions. MedGence formulates and documents products to align with diverse market frameworks.
Dietary Supplements (DSHEA / 21 CFR Part 111): Formulating immune-defense complexes with structure/function claims, backed by robust safety evaluations, heavy metal clearance (<0.1 ppm Pb/Cd/As/Hg), and pesticide residue screenings (USP <561>).
Botanical Drug Guidance: Supplying standardized Botanical Drug Substance (BDS) chemistry, manufacturing, and control (CMC) packages for Phase I/II IND filings.
Traditional Herbal Medicinal Products Directive (Directive 2004/24/EC): Qualifying products for THMPD registrations based on verified 30-year medicinal use documentation or well-established medicinal use (WEU).
Novel Foods & Food Supplements: Ensuring botanical extracts comply with European Pharmacopoeia (Ph. Eur.) microbiological criteria, polycyclic aromatic hydrocarbon (PAH) limits, and solvent residue thresholds.
Class 1.1 / 1.2 Innovative TCM Medicines: Full-spectrum R&D from formula optimization to clinical trials for hospital preparations and national NDA submissions under China's streamlined TCM innovation pathways.
ASEAN Harmonization: Rapid registration dossiers for South East Asian distribution channels complying with regional heavy metal, microbial, and stability testing standards.
Large-scale commercial buyers often encounter volatility in quality, clinical reproducibility, and intellectual property. MedGence eliminates these vulnerabilities with systematic industrial solutions.
The Challenge: Seasonal changes and soil variability alter active constituent levels in wild plants.
Our Solution: GACP Base Control & Origin Fingerprinting. We test samples from diverse origins and seasons, selecting raw ingredients that meet strict active component thresholds before batch manufacturing begins.
The Challenge: Discrepancies in sensory traits, solubility, or chemical potency between production runs.
Our Solution: Dual-Wavelength Fingerprinting & QbD. Every OEM production run is matched to verified reference chromatograms with similarity scores > 0.95, maintaining reliable batch-to-batch consistency.
The Challenge: Products facing customs rejection or recalls over unapproved solvents or unverified claims.
Our Solution: Complete Toxicology & Certificate Dossiers. Every commercial lot is shipped with comprehensive COAs, pesticide testing, residual solvent assays, and stability data.
The Challenge: Fear of proprietary formulation leakage to competing domestic or international brands.
Our Solution: Strict Entrusted CDMO Confidentiality. We operate under binding NDAs and compartmentalized manufacturing lines; your process parameters and recipes remain your exclusive intellectual property.
MedGence (Yineng Pharma), headquartered in Changsha, China, provides deep research infrastructure and scaled contract manufacturing for leading global enterprises.
Years Dedicated R&D
Scientists & Researchers
Pharma Groups & Hospitals
Classic TCM Formulas Modernized
Innovative Natural Drugs Developed
Hospital Preparation Registrations
Single-Herb Standards Established
Confidential Entrusted Supply
Our contract research and manufacturing protocols are validated by long-standing collaborations with major pharmaceutical groups, university teaching hospitals, and clinical TCM research institutions across China.
Tongrentang Group
China Resources Sanjiu
Sunflower Pharma
Livzon Pharma Group
Dihon Pharmaceutical
Golden Throat Group
Yangtze River Pharma
Beihai Gofar Biological
Humanwell Healthcare
SCIMYTH Pharma
Shandong Hanfang
Luoxin Pharma Group
Zhongsheng Pharma
Brilliance & Abundance
Apeloa Pharmaceutical
Heng Chang Pharma
Baotou TCM
Kamp Medicine
Guangxi Santo Pharma
Kangshou Pharma
Jiangxi Juwang
Beijing Tcmages
Guizhou Ruihe Pharma
CR Jinchan Pharma
Kangmei Pharma
Tianjicaotang Pharma
Kingstone Unite
Shuguang Hospital TCM
Hunan Affiliated TCM Hospital
First Hospital Hunan TCM
Second Xiangya Hospital
Second Hospital Hunan TCM
Zhuzhou Orthopedics TCM
Select from our validated CRO research packages or initiate custom batch manufacturing for active botanical ingredients and finished dosage forms.
Clear answers addressing technical validation, regulatory dossiers, IP protection, and manufacturing lead times.
Whether you require targeted active ingredient discovery, validated chromatographic method establishment, in vitro/in vivo preclinical testing, or high-volume cGMP formulation manufacturing, our scientists are prepared to review your project brief.
